Company record
Slate Run Pharmaceuticals
0 FDA warning letters since 2023 and 1 recall in the last 12 months.
Get an email the day FDA posts anything new about Slate Run Pharmaceuticals.
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Mar 4 | Class III | Slate Run Pharmaceuticals Drug |
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Are⦠Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion. FDA notice D-0343-2026 |